Max Healthcare Institute Limited reported robust growth for the financial year ended March 31, 2026. The company achieved a consolidated annual revenue of ₹8,37,345 lakh and a net profit of ₹1,44,241 lakh. The Board recommended a final dividend of ₹2 per equity share. Additionally, the company is expanding its hospital network with the construction of a new 712-bed facility in Lucknow and recently acquired a controlling stake in Kalinga Hospitals Limited.
Financial Performance Overview
For the financial year 2025-26, Max Healthcare demonstrated significant financial strength. The consolidated revenue from operations reached ₹8,37,345 lakh, marking a substantial increase over the previous year. The consolidated net profit for the year stood at ₹1,44,241 lakh. In recognition of this performance, the Board of Directors has recommended a final dividend of ₹2 per equity share, representing 20% of the face value of ₹10 per share, subject to shareholder approval.
Strategic Expansion and Acquisitions
The company is aggressively pursuing its growth strategy. The Board has approved the construction of Phase-I of the Max Super Specialty Hospital in Lucknow, Shaheed Path. This facility will be built on a 5-acre land parcel and will add a capacity of approximately 712 beds. The project is expected to be completed within 36 months of drawing approvals, with an estimated investment of ₹1,400 crore.
Furthermore, in a move to strengthen its presence in Eastern India, Max Healthcare acquired a 58.28% equity stake in Kalinga Hospitals Limited for an aggregate cash consideration of ₹29,797 lakh. Kalinga Hospital is a 250-bed NABH-accredited multi-specialty facility located in Bhubaneswar, Odisha.
Corporate Governance and Operational Updates
As part of its administrative realignment, the company is shifting its registered office from the State of Maharashtra to the State of Haryana. Additionally, the Board has approved the re-appointment of Mr. Anil Kumar Bhatnagar as a Non-Executive and Non-Independent Director for a term of three years, effective from October 1, 2026, to September 30, 2029. The company also announced the re-appointment of M/s. Chandra Wadhwa & Co. as the Cost Auditors for the financial year 2026-27.
Source: BSE
